Please use this identifier to cite or link to this item:
|Title:||EFFECTS OF THE REMOVAL OF THE EXCLUSION OF BIOSIMILARS FROM MEDICARE’S COVERAGE GAP DISCOUNT PROGRAM|
|Abstract:||Biosimilar competition provides an opportunity to dramatically reduce healthcare spending while simultaneously making life-saving drugs more accessible to patients. In 2018, Congress passed the Bipartisan Budget Act of 2018, which included a provision to remove the exclusion of biosimilars from Medicare Part D’s Coverage Gap Discount Program (CGDP), effectively eliminating one of the significant impediments to biosimilar adoption by Part D plans. This paper is the first to analyze the effects of this policy change on Part D plans’ coverage of reference biologics and biosimilars. Using CMS’s Medicare Part D plan, formulary, and cost files from 2016Q1-2021Q4 and historical pricing films from Micromedex RED BOOK, I analyze the effects of the policy change on various benefit designs from the percentage of plans covering the drug to utilization management tools like prior authorization and step therapy. I find that the policy change has a negative effect on reference biologic benefit design and a positive effect on biosimilar benefit design.|
|Type of Material:||Princeton University Senior Theses|
|Appears in Collections:||Economics, 1927-2023|
Files in This Item:
|WANG-SEAN-THESIS.pdf||730.84 kB||Adobe PDF||Request a copy|
Items in Dataspace are protected by copyright, with all rights reserved, unless otherwise indicated.